Pitfalls of HIV genotypic tropism testing after treatment interruption

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 1, 2013, Pages 188-189

  Wirden, Marc ^a,b,c   Soulié, Cathia ^a,b,c   Fourati, Slim ^a,b,c   Valantin, Marc Antoine ^a,b,c   Simon, Anne ^c   Ktorza, Nadine ^c   Tubiana, Roland ^a,b,c   Bonmarchand, Manuela ^c   Schneider, Luminita ^c   Calvez, Vincent ^a,b,c   Katlama, Christine ^a,b,c   Marcelin, Anne Genevieve ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b INSERM   (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CCR5 antagonist; R5 virus; Tropism determination; X4 virus

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; NONHUMAN; RETROSPECTIVE STUDY; VIRAL TROPISM;

ANTI-HIV AGENTS; DATABASES, FACTUAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT OUTCOME; VIRAL TROPISM;

EID: 84871205423     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks362     Document Type: Article

References (6)

1. Harrigan PR, Geretti AM. Genotypic tropism testing: evidence-based or leap of faith? AIDS 2011; 25: 257-64.
2. McGovern RA, Thielen A, Mo T et al. Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 2010; 24: 2517-25.
3. Wirden M, Delaugerre C, Marcelin AG et al. Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy. Antimicrob Agents Chemother 2004; 48: 644-7.
4. Ghosn J, Wirden M, Ktorza N et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19: 1643-7.
5. Weiser B, Philpott S, Klimkait T et al. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 2008; 22: 469-79.
6. Hunt PW, Harrigan PR, Huang W et al. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis 2006; 194: 926-30.